rosiglitazone has been researched along with Coronary Restenosis in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Dai, J; Hua, J; Mao, W; Qiu, Y; Xu, X; Zhou, X; Zhu, M | 1 |
| Bruskina, O; Byrne, RM; Cagliero, E; Crimins, J; Daher, M; Finn, AV; Gold, HK; Hendricks, M; John, MC; Kastrati, A; Nadelson, J; Oh, JS; Palacios, I; Schömig, A | 1 |
| Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW | 1 |
| Evans, M; Rees, A; Roberts, AW; Thomas, A | 1 |
| Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S | 1 |
| Ahn, CW; Cha, BS; Choi, D; Choi, SH; Jang, Y; Kim, SK; Ko, YG; Lee, HC; Lim, SK | 1 |
| Chilton, R; Sulistio, MS; Thukral, N; Zion, A | 1 |
3 review(s) available for rosiglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Different Effects of Thiazolidinediones on In-Stent Restenosis and Target Lesion Revascularization after PCI: A Meta-Analysis of Randomized Controlled Trials.
Topics: Angioplasty, Balloon, Coronary; Constriction, Pathologic; Coronary Angiography; Coronary Restenosis; Drug-Eluting Stents; Humans; Myocardial Revascularization; Odds Ratio; Percutaneous Coronary Intervention; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome | 2017 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Restenosis; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Humans; Hyperglycemia; Insulin Resistance; Lipoproteins; Matrix Metalloproteinases; Metformin; Muscle, Smooth, Vascular; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2003 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides | 2008 |
4 trial(s) available for rosiglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Rosiglitazone; Stents; Thiazolidinediones; Vasodilator Agents | 2009 |
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Stents; Thiazolidinediones | 2004 |
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
Topics: Adult; Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2004 |
1 other study(ies) available for rosiglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Diabetes drug may also benefit blood vessels.
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2003 |